On September 10, the marketing application for metabolism-related steatohepatitis with simeglutide injection was approved by the China National Drug Administration. It is suitable for treating non-cirrhosis adult patients with metabolism-related steatohepatitis with moderate to severe liver fibrosis. It has become the first and only GLP-1 RA drug approved for the treatment of metabolism-related steatohepatitis in China so far.
智通財經·09/10/2026 02:57:02
語音播報
On September 10, the marketing application for metabolism-related steatohepatitis with simeglutide injection was approved by the China National Drug Administration. It is suitable for treating non-cirrhosis adult patients with metabolism-related steatohepatitis with moderate to severe liver fibrosis. It has become the first and only GLP-1 RA drug approved for the treatment of metabolism-related steatohepatitis in China so far.